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a  b  s  t  r  a  c  t
MDMA  (“ecstasy”)  is  widely  used  as  a  recreational  drug,  although  there  has  been  some  debate  about
its  neurotoxic  effects  in  humans.  However,  most  studies  have  investigated  subjects  with  heavy  use  pat-
terns,  and the  effects  of transient  MDMA  use  are  unclear.  In  this  review,  we therefore  focus  on  subjects
with  moderate  use patterns,  in  order to  assess  the  evidence  for  harmful  effects.  We  searched  for  studies
applying  neuroimaging  techniques  in  man.  Studies  were  included  if they  provided  at  least  one  group  with
an  average  of  <50  lifetime  episodes  of  ecstasy  use or an  average  lifetime  consumption  of  <100  ecstasy
tablets.  All  studies  published  before  July 2015  were  included.  Of  the  250  studies  identiﬁed  in the  database
search,  19 were  included.
There is no convincing  evidence  that  moderate  MDMA  use  is  associated  with  structural  or  functional
nedioxymethamphetamine
ing
cts
ects
brain  alterations  in  neuroimaging  measures.  The  lack  of  signiﬁcant  results  was  associated  with  high
methodological  heterogeneity  in terms  of  dosages  and  co-consumption  of other  drugs,  low  quality  of
studies  and  small  sample  sizes.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This is an  open  access  article  under  the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ity
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Table 2
Characteristics of all included studies.
Centre Authors and year
of  publication
Study
design
Modality  n subjects
overlapping withn
User group Control group
p r n m/f  age n m/f  age
Aachen/Cologne
Daumann et al. (2003a)1 X fMRI 72, 83,4 11 8/3 23.3 11 8/3 25.6
Daumann et al.
(2003b)2 X fMRI 7
1
8 4/4 25.3
8 4/4 25.648 4/4 26.4
Daumann et al. (2011)3 X sMRI 81, 424, 155, 186 42 30/12 23.6 16 9/7 26.3
Koester et al. (2012)4 X sMRI 81,423, 155, 186 42 30/12 23.6 16 9/7 26.3
Becker et al. (2013)5 X fMRI 153,4 17 14/3 22.73 12 11/1 23.43
Koester et al. (2013)6 X fMRI 183,4 18 12/6 22.9 15 9/6 26.5
Amsterdam/Utrecht
Reneman et al. (2001)7 X SPECT 158 15 9/6 24.41 15 7/8 26.11
de Win  et al. (2007)8 X sMRI 3011 30 12/18 22.52 – – –
Jager et al. (2007)9 X fMRI 2511 25 9/16 22.82 24 8/16 23.02
de Win  et al. (2008)10 X sMRI, SPECT 309, 2510 59 25/34 23.02 56 23/33 23.12
Copenhagen Erritzoe et al. (2011)11 X PET – 10 9/1 23.3 21 17/4 23.8
Granada Moreno-Lopez et al. (2012)12 X PET – 49 41/8 32.7 – – –
Nashville
Karageorgiou et al. (2009)13 X fMRI 514,1416, 1017 14 10/4 26.0 10 5/5 22.9
Bauernfeind et al. (2011)14 X fMRI 513,16, 1017 20 n/p n/p 20 n/p n/p
Di Iorio et al. (2012)15 X PET – 14 0/14 21.6 10 0/10 21.6
Salomon et al. (2012)16 X fMRI 1413, 514,1017 14 10/4 26.0 10 5/5 22.9
Watkins et al. (2013)17 X fMRI 1013,16,1014 23 17/6 24.6 11 5/6 22.4
New Haven Jacobsen et al. (2004)18 X fMRI – 6 2/4 17.3 6 2/4 17.1
San Diego Mackey et al. (2014)19 X sMRI – 165 101/64 20.9 46 21/25 21.0
1Calculated weighted mean, 2Age at follow up, 3 Age at baseline.
Table 3
Characteristics of MDMA  use.
Centre Authors and year
of  publication
Data provided about lifetime doses of ecstasy in original publication Calculated
lifetime
dose (mg)Cumulative lifetime dose Usual dose
per  occasion
(tablets)
Maximum dose
per  occasion
(tablets)
Age  at
onset of
use
Time  since
last  use
(days)
Duration  of
use  (days)
Tablets Episodes mg
Aachen/Cologne
Daumann  et al.
(2003a)
27.36  n/p n/p 1.57 n/p 20.2 330.1 486.0 2071.15
Daumann et al.
(2003b)
74.50  n/p n/p 1.66 n/p 22.8 23.0 1028.7 5639.65
56.25 n/p n/p 1.44 n/p 19.0 62.4 552.9 4258.13
Daumann et al.
(2011)
2.89  n/p n/p 1.02 1.58 20.4 670.0 n/p 218.77
Koester et al. (2012) 2.89 n/p n/p 1.02 1.58 20.4 670.0 n/p 218.77
Becker et al. (2013) 9.503 n/p n/p 1.36 2.02 20.6 86.3 n/p 719.15
Koester et al. (2013) 2.65 n/p n/p 1.18 n/p n/p 930.7 n/p 200.61
Amsterdam/Utrecht
Reneman et al.
(2001)
28.6  n/p n/p 1.4 n/p n/p 108 1492.4 2165.02
de Win  et al. (2007) 1.8 n/p n/p n/p n/p n/p 53.9 14.7 136.26
Jager et al. (2007) 2.0 n/p n/p n/p n/p n/p 77.7 36 151.40
de Win  et al. (2008) 6.0 n/p n/p n/p n/p n/p 130.9 142.8 454.20
Copenhagen  Erritzoe et al.
(2011)
60  18 n/p 1.8 n/p 18.2 122 1713 4542.00
Granada  Moreno-Lopez et al.
(2012)
13.41  n/p n/p n/p n/p n/p 230.64 511 1015.14
Nashville
Karageorgiou et al.
(2009)
n/p  29.6 2365.2 n/p n/p n/p 669.4 n/p 2912.94
Bauernfeind et al.
(2011)
n/p  33.25 2692.38 n/p n/p n/p 478.0 n/p 3272.13
Di Iorio et al. (2012) n/p 13.5 1400.00 n/p n/p n/p 689.5 n/p 1328.54
Salomon et al.
(2012)
n/p  29.6 2365.2 n/p n/p n/p 669.4 n/p 2912.94
Watkins et al.
(2013)
n/p  16.0 1250.0 n/p n/p n/p 476.0 n/p 1574.56
New  Haven Jacobsen et al.
(2004)
n/p  10 n/p n/p n/p 15.8 n/p 547.51 984.10
San  Diego Mackey et al.
(2014)
n/p  3.1 n/p n/p n/p 19.0 n/p 675.3 305.07
n/p = not provided.
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Table 4
Co-consumption of other drugs and times of abstinence from other drugs.
Centre Authors and year
of  publication
Reported signiﬁcant differences
between MDMA group and control
or between baseline and follow-up
in use of other illicit drugs
Reported signiﬁcant
differences in use of
alcohol  and nicotine
Calculated signiﬁcant
differences in lifetime
dose  of other drugs
(unpaired  t-test, p < 0.05)
Required abstinence from different drugs (days)
Alcohol Nicotine Cannabis Other drugs
Aachen/Cologne
Daumann et al. (2003a) n/p1 n/p Not enough data provided 7 n/p 0 7
Daumann et al. (2003b) none n/p Not enough data provided n/p n/p 0 7
Daumann et al. (2011) n/p2* n/p Cannabis, amphetamines5,6 7 n/p 0 7
Daumann et al. (2011) n/p2 n/p Cannabis, amphetamines5,6 7 n/p 1 7
Koester et al. (2012) Amphetamines* none* – 7 n/p 1 7
Becker et al. (2013) n/p2* n/p Cannabis, amphetamines5.6 7 n/p 1 7
Amsterdam/Utrecht
Koester et al. (2013) n/p3 none Not enough data provided n/p n/p 21 21
Reneman et al. (2001) Cocaine* none – n/p n/p 14 14
de  Win  et al. (2007) none none – 7 0 14 14
Jager  et al. (2007) Cannabis,
amphetamine,
cocaine*
Alcohol* – 7 n/p 14 14
Copenhagen  de Win  et al. (2008) n/p4* none Not enough data provided n/p n/p 7 7
Granada  Erritzoe et al. (2011) n/a (no control
group)*
n/a (no control group)* – 15 0 15 15
Nashville
Moreno-Lopez et al. (2012) Cocaine* none (nicotine n/p)* – 2 n/p 2 14
Karageorgiou et al. (2009) n/p* n/p* Not enough data provided 2 n/p 14 14
Bauernfeind et al. (2011) Psilocybin* none* – 3 n/p 14 14
Di  Iorio et al. (2012) Cocaine n/p Not enough data provided 2 n/p 2 14
Salomon et al. (2012) Cannabis, cocaine,
LSD,  psilocybin,
opium*
none* – 2 n/p 14 14
New  Haven Watkins et al. (2013) n/p none Not enough data provided n/p n/p n/p n/p
San  Diego Jacobsen et al. (2004) Cannabis* Nicotine, alcohol* – n/p n/p 3 3
1 No previous or current history of regular drug use or regular heavy alcohol use in control group, 2 Drug-naïve control group, 3 MDMA users reported more amphetamine and cocaine use than controls, 4 Control group < 15
lifetime  episodes of cannabis use and no history of other illicit drugs, 5 Studies investigated amphetamine-type stimulants and not MDMA  exclusively, 6 No data for alcohol and nicotine provided, n/a = not applicable, n/p = not
provided,  *Accounting for at least one of these potential confounders.
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 memory). For details see Table 5. Of the studies reporting
 task performance, all (Daumann et al., 2003a,b; Becker
3; Jager et al., 2007; Karageorgiou et al., 2009; Watkins
13) but two (Jacobsen et al., 2004; Koester et al., 2013)
no signiﬁcant differences between users and controls.
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showed no signiﬁcant differences between the user and
ol group for any of the paradigms.
r et al. prospectively investigated associative memory in a
f amphetamine-type stimulants users with limited experi-
DMA  and/or other amphetamines (Becker et al., 2013). At
e brain level, no signiﬁcant differences were reported. An
sis of the hippocampus and the parahippocampus yielded
d encoding-related activity in the left parahippocampal
ich was negatively correlated with interim use of MDMA,
annabis or other amphetamines. The authors noted that
es in hippocampal activity between interim abstinent
and subjects who  continued use of amphetamine-type
ts  were already present at baseline. They discuss differ-
ions of abstinence as an explanation for this ﬁnding and
at the observed results in the parahippocampal gyrus were
en by a relative increase in activity in the interim absti-
rs, which might be due to recovery during this time of
e.
er et al. examined decision-making in amphetamine-type
ts  users (Koester et al., 2013). The control group had no
ce with any illicit drugs, including cannabis. No attempt
e to disentangle use of MDMA  and other amphetamines.
had to choose between control gambles with a 50% chance
 or winning a small amount of money and experimen-
les with a low or a high chance of losing or winning.
ve controls chose fewer experimental gambles than the
mine-type stimulants group. With the FMRIB’s Local Anal-
ixed Effects, no signiﬁcant differences were observed;
, with ordinary least squares, they observed an increased
nal in the right parietal lobe during high probabilities of
ns et al. tested semantic memory in a cohort that consisted
f subjects already examined in the ﬁrst two fMRI stud-
the same centre (Bauernfeind et al., 2011; Karageorgiou
9). The MDMA  user group showed signiﬁcantly more con-
 of a variety of other drugs (cannabis, cocaine, opium,
, LSD, psilocybin). During semantic encoding, the user
wed greater activation in the left precuneus and the right
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parietal lobule or the left precuneus.
eorgiou et al. tested motor function with fMRI using a
pping task (1-, 2-, 4-tap task) (Karageorgiou et al., 2009).
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The ROI analysis yielded an increased BOLD signal and
se in percent activated voxels in the right supplemen-
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mpared with controls. No dose dependent effect was
. For the within-group comparison, a positive correla-
 described between the amount of MDMA  use and the
nal increase in the right putamen and the right pal-
 well as with the spatial extent of activation in the right
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plementary motor area were observed in the within-
mparison and no correlation was  found between lifetime
 of alcohol, cannabis, cocaine and methamphetamine use
 signal. For the tap-4 condition, a signiﬁcant association
 between alcohol use and percentage of activated vox-
 left postcentral and left precentral cortex. No association
d for other drugs (cannabis, cocaine, methamphetamine).
 et al. reanalysed the data set from Karageorgiou et al.
egional coherence and functional connectivity (Salomon
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Table 5
Included functional imaging studies: Imaging results.
Authors and year of
publication
Modality Tested domain Regions analysed Threshold Results (user group compared with
controls, if not indicated otherwise)
Daumann et al.
(2003a)
fMRI Working memory (n-back task) Whole brain p < 0.05 corrected, p < 0.01 and
p < 0.001 uncorrected,
cluster ≥ 5
0-back: No signiﬁcant differences
1-back:  Right parietal cortex ↑ (p < 0.001
uncorrected)
2-back: Right and left parietal cortex ↑
(p < 0.01, uncorrected)
Daumann  et al.
(2003b)
fMRI Working memory (n-back task) Whole brain p < 0.001, uncorrected,
cluster ≥ 5
0-back: No signiﬁcant differences
1-back:  Polydrug user versus control
group: No signiﬁcant differences; Pure
MDMA user vs. control group: Inferior
temporal, angular region ↓; Pure MDMA
user vs. polydrug user: striate cortex ↓,
premotor cortex ↑
2-back:  Polydrug user versus control
group: No signiﬁcant differences; Pure
MDMA user versus control group: Angular
gyrus ↓; Pure MDMA user versus polydrug
user: Angular gyrus ↓
Becker
et al.
(2013)
fMRI
Associative memory (encoding and
retrieval task)
Whole brain p < 0.05, corrected (FWER),
cluster ≥ 10
No signiﬁcant differences
ROI: Hippocampus,
parahippocampus
p < 0.05, corrected (FWER,
small volume correction),
cluster  ≥ 10
Left parahippocampal gyrus: encoding
related activity ↓
Koester et al.
(2013)
fMRI Decision making
(gambling task)
Whole brain p < 0.05, corrected, cluster
Z  > 2.3
FLAME:  No signiﬁcant differences
OLS: Right parietal lobe ↑ (high probability
of winning)
Jager  et al. (2007) fMRI
Working memory (item-recognition
task)
Whole brain, ROI: left superior
parietal cortex, left dorsolateral
prefrontal  cortex, anterior
cingulate  cortex, left fusiform
gyrus
p  < 0.05, corrected (FWER) No signiﬁcant differences
Selective attention (visuo-auditory
selective  attention task)
Whole  brain, ROI: Right inferior
frontal gyrus, left and right
auditory cortex, anterior cingulate
cortex, left precentral gyrus, left
insula, visual cortex, left inferior
frontal gyrus
Associative  memory (pictorial
associative  memory task)
Whole  brain, ROI: Right and left
(para)hippocampal regions, right
and left dorsolateral prefrontal
cortex,  right and left middle
occipital  gyrus, anterior cingulate
cortex, right and left inferior
frontal  gyrus
28
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Table 5 (Continued)
Authors and year of
publication
Modality Tested domain Regions analysed Threshold Results (user group compared with
controls, if not indicated otherwise)
Karageorgiou et al.
(2009)
fMRI  Motor function (motor tapping task) Supplementary motor area,
precentral gyrus, caudate,
putamen,  pallidum, thalamus,
postcentral  gyrus
Between group contrast:
p  ≤ 0.05, uncorrected,
cluster ≥ 26
Within-group contrast:
p  < 0.001, uncorrected
Between group effect: Right
supplementary  motor area ↑ (tap 4
condition)
Within-group dose effects: Percent BOLD
signal change: Right putamen, right
pallidum ↑, Percent activated voxels: Right
precentral cortex, right and left thalamus ↑
Bauernfeind  et al.
(2011)
fMRI  Visual stimulation (two-colour visual
stimulation task)
Bilateral geniculate nucleus,
bilateral  BA17, bilateral BA 18
Intensity:  p < 0.05, corrected,
cluster ≥ 90 voxels (Monte
Carlo simulation to generate
p < 0.05 corrected for FWER)
Extent: p < 0.001, uncorrected
Within-group dose effect: Activation in
lateral geniculate nucleus, BA 17, BA18 ↑,
spatial extent in BA 17 and 18 ↑, after
adjusting for different scanners and
stimulus delivery methods, only activation
in lateral geniculate nucleus remained
signiﬁcant
Between-group: No signiﬁcant differences
in activation and spatial extent (spatial
extent in BA17 and 18 ↑ in heavy users,
signal intensity in lateral geniculate
nucleus ↑ in low users)
Salomon et al.
(2012)
fMRI Motor function (motor tapping task);
coherence and functional connectivity
Supplementary motor area,
precentral gyrus, caudate,
putamen,  pallidum, thalamus,
postcentral  gyrus,
pontomesencephalic pontine
raphé  region
p ≤ 0.05, corrected (Bonferroni
correction)
Intra-regional coherence: Bilateral
thalamus (low frequencies) ↓, right
thalamus (medium frequencies) ↓
Functional connectivity: Left caudate –
right thalamus, right caudate – right
postcentral gyurs, right supplementary
motor area – right precentral gyrus,
bilateral thalamus ↓
Watkins et al.
(2013)
fMRI Semantic memory (encoding and
recognition of words)
Cortex p < 0.01, cluster ≥ 276 voxels
(Monte Carlo simulation to
generate p < 0.05 corrected for
FWER)
Left precuneus, right superior parietal
lobule (semantic encoding)↑
Jacobsen et al.
(2004)
fMRI Working memory, selective and
divided attention (binaural and
dichotic verbal and binaural 3- back,
auditory 2-back task)
Hippocampus p ≤ 0.01, uncorrected,
cluster ≥ 8
Left hippocampus ↑ (dichotic 2-back
condition) (0.8)
↑ = increase, ↓ = decrease, ROI = Region of interest, FWER = family wise error rate, FLAME = FMRIB’s Local Analysis of Mixed Effects, OLS = ordinary least squares.
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Table  6
Included MRI  studies applying further techniques.
Authors and
year  of
publication
Modality Tested domain Regions analysed Threshold Results (user group compared
with  controls, if not indicated
otherwise)
Daumann et al.
(2011) MRI
DTI (fractional anisotropy) White matter p < 0.05, FWER corrected,
cluster-based threshold
No  signiﬁcant differences
sMRI  (VBM) Grey matter
Koester et al.
(2012) MRI
sMRI (VBM)
Whole brain p < 0.05, FWER corrected,
cluster-based threshold
Cortical thickness: No
signiﬁcant differences
Cortical  grey matter volume:
Volume  in orbitofrontal (left)
and occipital (right) regions↓
ROI: hippocampus,
thalamus, nucleus
accumbens, putamen,
nucleus  caudatus, globus
pallidus
FDR No signiﬁcant differences
de Win  et al.
(2007) MRI
1H-MRS
(N-acetylaspartate, choline,
myo-inositol,  creatine)
Mid-frontal, mid-occipital
grey  matter, left centrum
semiovale
p  < 0.05, post hoc
Bonferroni correction:
1H-MRS p < 0.006, DTI:
p  < 0.010,
rrCBV p < 0.005
p < 0.05, uncorrected: No
signiﬁcant differences
DTI  (fractional anisotropy,
apparent  diffusion)
Thalamus, globus pallidus,
putamen, caudate nucleus,
centrum  semiovale
p < 0.05, uncorrected: FA:
centrum semiovale ↑, ADC:
thalamus  ↓; Bonferroni
correction  : No signiﬁcant
differences
PWI (relative regional
blood  ﬂow)
Thalamus, globus pallidus,
putamen, caudate nucleus,
dorsolateral  frontal,
mid-frontal, occipital,
superior  parietal, temporal
grey  matter, centrum
semiovale
p  < 0.05, uncorrected:
Thalamus, dorsolateral frontal
cortex, superior parietal grey
matter ↓; p < 0.005 Bonferroni
correction: dorsolateral frontal
grey matter↓
de Win  et al.
(2008) MRI
1H-MRS
(N-acetylaspartate, choline,
myo-inositol,  creatine)
Mid-frontal, mid-occipital
grey  matter, left
frontoparietal white matter
p  < 0.05, uncorrected
p < 0.05, uncorrected
No signiﬁcant differences
DTI  (fractional anisotropy,
apparent  diffusion)
Thalamus, globus pallidus,
putamen, caudate
nucleus,  frontoparietal
white  matter
FA: thalamus, frontoparietal
white  matter ↓, globus pallidus
↑; ADC: thalamus ↑
PWI  (relative regional
blood  ﬂow)
Thalamus, globus pallidus,
putamen, caudate nucleus,
dorsolateral  frontal,
mid-frontal, occipital,
superior  parietal tempor,
temporal  grey matter
Globus pallidus, putamen ↓
Mackey et al.
(2014)
MRI  sMRI (VBM) Whole brain p < 0.01, cluster-extent
correction (132 voxels)
Grey  matter volume: left
ventral  anterior putamen ↑,
right dorsolateral cerebellum,
right inferior parietal cortex↓
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